Hims & Hers Health, Inc. Faces Class Action Following Stock Plunge Amid Allegations of Misleading Practices

Understanding the Hims & Hers Health, Inc. Class Action Lawsuit

In recent events, Hims & Hers Health, Inc. found itself amidst a challenging situation, experiencing a dramatic stock drop of 14.73% that raises caution for its investors. The stumble occurred on July 29, 2026, following serious allegations concerning the company’s privacy practices and misleading representations made to shareholders.

The Lawsuit Details

The Law Offices of Frank R. Cruz have initiated a class action lawsuit against Hims & Hers, targeting those who acquired shares from August 4, 2025, to July 29, 2026. The complaint, labeled Velanki v. Hims & Hers Health, Inc., was filed in the U.S. District Court for the Northern District of California on September 1, 2026. Investors seeking justice must file motions to be considered for lead plaintiff status by November 2, 2026.

Allegations of Misconduct

According to the lawsuit, Hims & Hers allegedly engaged in deceptive practices that misled investors by failing to disclose multiple significant facts. The accusations include:
1. Sharing of Health Data: The company purportedly shared sensitive customer health data with third-party advertisers, such as Meta Platforms and Snap. This was contrary to their public marketing message, which emphasized a commitment to stringent privacy measures.
2. Questionable Billing Practices: It is claimed that Hims & Hers charged customers for prescriptions soon after submitting intake forms, despite assurances that they would have medical consultations first.
3. Regulatory Scrutiny: The actions of Hims & Hers drew the attention of regulatory bodies, raising concerns about potential penalties and fees as a consequence of non-compliance with privacy norms.
4. Inaccurate Business Statements: The lawsuit argues that the company’s favorable statements about its business viability were misleading, given the underlying issues.

Impact on Investors

The fallout from these revelations became evident on the day the allegations surfaced, resulting in a sharp decline in the company's stock price, dropping $4.32 to close at $25.00 per share. This created a substantial financial setback for investors.

What Should Investors Do?

Investors who sustained losses due to record-keeping from August 4, 2025, through July 29, 2026, are encouraged to join the class action lawsuit. Those interested in taking a more active role can file motions to become lead plaintiffs, offering representation for all affected investors.

However, it's important to note that participating in the lead plaintiff role is not necessary to obtain restitution. Investors have the option to remain absent from the class while still having a claim to any recovery awarded through the case.

Moving Forward

The November 2 deadline serves as a critical moment for potential plaintiffs wishing to play a role in legal proceedings. The Law Offices of Frank R. Cruz are poised to assist those who wish to explore their legal options concerning this case.

For further inquiries, investors may reach out by emailing [email protected] or calling their office directly. It’s advisable for investors to thoroughly consider their options and seek legal guidance as they navigate this complex situation.

Conclusion

The ongoing struggles of Hims & Hers Health, Inc. portray a significant chapter in the narrative of corporate accountability and securities regulation. As the class action progresses, it will serve as a crucial test of how such allegations are managed in the fast-evolving healthcare and wellness sectors.